Is the National Breast Pathology Update Course of interest? This virtual 1 day course will cover aspects of pathology diagnosis including lectures and workshops. Join here: ow.ly/wXTT50R92Uf for 5 #CPD credits.

The latest version of the prostate cancer guidelines are now summarised and available. You have heard the rumours now read what we changed and why! European Urology European Association of Urology (EAU) Derya Tilki, MD authors.elsevier.com/c/1iwC714kplyy…

The 2nd Annual #DCIS Patient Forum will be held virtually on Sat, May 18th at 9 am! A variety of topics will be covered including 👉understanding your pathology report 👉radiation therapy for DCIS 👉+ all sessions will have a Q&A component Register: redcap.partners.org/redcap/surveys…

Rockport 💙

Carolina Breast Cancer Study: assoc between MHC I +II and race. (total n=1630, 787=black; 68% HR+/HER2-) presented by Sonya Reid MHCI + II more common in black in HR+/HER2- BC (this could potentially translate into improved response to IO) OncoAlert #bcsm #ASCO24

Check out our poster (board #147) looking at the predictive value of TILs in pts with TNBC treated with neoadjuvant chemotherapy in TBCRC 030 TILs assessed by pathologists and #AI algorithms were predictive of pathologic response Erica Mayer Dana-Farber’s Breast Oncology Center OncoAlert

#ASCO24 Poster Session | Comprehensive analysis of TROP2, PD-L1, stromal (s)#TILs, and HER2 expression patterns in patients with metastatic HR+HER2- #BreastCancer | Abstract: 1062 | Poster Bd #: 40 Chiara Corti #AnaGarridoCastro Sara Tolaney Nancy Lin, MD Dr. E Mittendorf Rinath Jeselsohn G Curigliano MD PhD

#ASCO24 Poster Session | Correlation of #TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for #TNBC in TBCRC 030 Guilherme Nader Marta Erica Mayer Adam Brufsky Lisa Carey, MD, ScM, FASCO Mothaffar Rimawi 👉meetings.asco.org/abstracts-pres…

Fell in love with coastal Massachusetts 🦋

Can ADCs help prevent BC relapse with maintained QoL? Glad to share the final analysis of ATEMPT, out in JCO: among 383 pts with stage I HER2+ BC receiving T-DM1, 5y iDFS was 97%, with 3 (<1%) distant events. Deep dive in the study & biomarkers below🧵1/10 ascopubs.org/doi/10.1200/JC…

I am super excited to share that I'll be giving a talk about our project at the ISEH Meeting at the end of August! First time at ISEH and first oral presentation!! Super grateful for the opportunity. Many thanks to amazing mentors Peter van Galen Mahasweta Gooptu Andy Lane.

The world of pathology and pathologists all over the world lost a giant. His legacy will live on forever.

Applicants to #pathmatch2025 : Join our first virtual open house session on Aug 19, 7 pm US Eastern! Join our dept leaders, program directors and trainees for a friendly chat about the Mass General Brigham residency program MGH Pathology🔬 Registration: partners.zoom.us/meeting/regist…

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive #BreastCancer: 5-Year Results and Correlative Analyses From #ATEMPT 👉pubmed.ncbi.nlm.nih.gov/38935923/ Paolo Tarantino Sara Tolaney Nabihah Tayob Ada Waks Antonio Wolff, MD (#HealthPolicyIsEconomicPolicy)

“All we are is dust in the wind” American Museum of Natural History

Continuing Dana-Farber’s Breast Oncology Center effort led by Nancy Lin, MD for patient population with limited options: A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases #brainmets in patients with HER2+ MBC #bcsm aacrjournals.org/clincancerres/…

📰Check out this recently published phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for #CentralNervousSystem metastases in patients with HER2-positive #BreastCancer. 🔓pubmed.ncbi.nlm.nih.gov/39226397/ Antonio Giordano, MD PhD Qingchun Jin Busem Binboga Kurt Nabihah Tayob Erica Mayer